{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:17:05Z","timestamp":1769066225054,"version":"3.49.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This research received external funding from the Association of Medical Diabetologists (Associazione Medici Diabetologi, AMD)."},{"name":"This research received external funding from the Association of Medical Diabetologists (Associazione Medici Diabetologi, AMD)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We evaluated the proportion of Type 2 diabetes (T2D) patients with chronic kidney disease (CKD) participating in the AMD (Association of Medical Diabetologists) Annals initiative who met the eligibility criteria for phase III-studies on finerenone, showing its renal and cardiovascular benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This analysis involved all T2D patients seen in 2019 in 282 diabetes centers in Italy, for whom data on kidney function (estimated glomerular filtration rate and albuminuria) were available. Data are presented separately for different scenarios, covering the population with main eligibility criteria for inclusion in the FIDELIO-DKD and FIGARO-DKD trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 343,037 T2D patients involved in the analysis, 5.4% met the eligibility criteria of the FIDELIO-DKD study (13.3% if we consider the population with fundus data) and 22.3% met those of the FIGARO-DKD trial. Overall, 110,000 (33%) patients were eligible for treatment with finerenone, with a male prevalence, an average age of 71\u00a0years, and good control of the main risk factors (HbA1c 7.3%; BP 138\/76\u00a0mmHg; LDL-c 87\u00a0mg\/dl), albeit with large percentages of not well controlled patients (50% with SBP\u2009&amp;gt;\u2009140\u00a0mmHg;\u2009&amp;gt;\u200930% with LDL-c\u2009&amp;gt;\u2009100\u00a0mg\/dl). Over 12% were on sodium\/glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists. Based on the event rate from the FIDELITY pooled analysis, the number of potentially avoidable events was 21.7 per 1000 eligible patients for the cardiovascular composite outcome and 16.7 for the renal outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis showed that approximately 33% of patients with T2D present the main eligibility criteria for treatment with finerenone and could therefore benefit from it in the near future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-024-02171-8","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T12:29:11Z","timestamp":1734265751000},"page":"589-596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Generalizability of kidney and cardiovascular protection by finerenone to the\n                    <i>real world<\/i>\n                    in Italy: insights from Fidelio and Figaro studies"],"prefix":"10.1093","volume":"38","author":[{"given":"Salvatore","family":"De Cosmo","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Scientific Institute \u201cCasa Sollievo Della Sofferenza\u201d, San Giovanni Rotondo, FG, Italy 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pontremoli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genoa and I.R.C.C.S., Viale Benedetto XV, 16125, Genoa, Italy 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0778-4130","authenticated-orcid":false,"given":"Annalisa","family":"Giandalia","sequence":"additional","affiliation":[{"name":"Department of Human Pathology of Adulthood and Childhood \u201cG. Barresi\u201d, University of Messina, Messina, Italy 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Manicardi","sequence":"additional","affiliation":[{"name":"AMD Foundation, Viale Delle Milizie, Rome, Italy 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Rocca","sequence":"additional","affiliation":[{"name":"\u201cG. Segalini\u201d H. Bassini Cinisello Balsamo ASST Nord, Milan, Italy 5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Nicolucci","sequence":"additional","affiliation":[{"name":"CORESEARCH \u2013 Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy 6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Rossi","sequence":"additional","affiliation":[{"name":"CORESEARCH \u2013 Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy 6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lucisano","sequence":"additional","affiliation":[{"name":"CORESEARCH \u2013 Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy 6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giusi","family":"Graziano","sequence":"additional","affiliation":[{"name":"CORESEARCH \u2013 Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy 6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Di Bartolo","sequence":"additional","affiliation":[{"name":"Department of Specialist Medicine, Ravenna Diabetes Center, Romagna Local Health Authority, Ravenna, Italy 7"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziano","family":"Di Cianni","sequence":"additional","affiliation":[{"name":"Diabetes and Metabolic Diseases Unit, Health Local Unit North-West Tuscany, Leghorn, Italy 8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Candido","sequence":"additional","affiliation":[{"name":"Diabetes Centre, University of Trieste, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy 9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina T.","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy 10"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the AMD Annals Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,15]]},"reference":[{"key":"2026012110525680800_CR1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","article-title":"Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016","volume":"94","author":"Xie","year":"2018","journal-title":"Kidney Int"},{"issue":"5S","key":"2026012110525680800_CR2","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2026012110525680800_CR3","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"key":"2026012110525680800_CR4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: a collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"},{"key":"2026012110525680800_CR5","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"37","author":"TuFle","year":"2014","journal-title":"Diabetes Care"},{"key":"2026012110525680800_CR6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11892-006-0083-y","article-title":"Diabtic nephropathy: worldwide epidemic and effects of current treatment on natural history","volume":"6","author":"Rossing","year":"2006","journal-title":"Curr Diab Rep"},{"key":"2026012110525680800_CR7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40620-018-00561-3","article-title":"Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals","volume":"32","author":"Viazzi","year":"2019","journal-title":"J Nephrol"},{"key":"2026012110525680800_CR8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s001250050895","article-title":"Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure","volume":"41","author":"FioreFo","year":"1998","journal-title":"Diabetologia"},{"key":"2026012110525680800_CR9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2026012110525680800_CR10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40620-019-00650-x","article-title":"Diabetic kidney disease: new clinical and therapeutic issues: Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on \u201cThe natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function\u201d","volume":"33","author":"Pugliese","year":"2020","journal-title":"J Nephrol"},{"key":"2026012110525680800_CR11","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s00125-018-4691-2","article-title":"Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicentre study","volume":"61","author":"Penno","year":"2018","journal-title":"Diabetologia"},{"key":"2026012110525680800_CR12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1159\/000508983","article-title":"Precision nephrology is a non-negligible state of mind in clinical research: remember the past to face the future","volume":"144","author":"Provenzano","year":"2020","journal-title":"Nephron"},{"issue":"2","key":"2026012110525680800_CR13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/dom.14888","article-title":"Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: an updated meta-analysis of randomized controlled trials with external adjudication of events","volume":"25","author":"Mannucci","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026012110525680800_CR14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"2026012110525680800_CR15","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.3390\/ijms24043427","article-title":"Endothelin receptor antagonists in kidney disease","volume":"24","author":"Martinez-Diaz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026012110525680800_CR16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebocontrolled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"2026012110525680800_CR17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharma-col"},{"key":"2026012110525680800_CR18","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/j.2040-4603.2014.tb00569.x","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"key":"2026012110525680800_CR19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for Finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"2026012110525680800_CR20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012110525680800_CR21","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with Finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012110525680800_CR22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026012110525680800_CR23","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2026012110525680800_CR24","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110672","article-title":"The AMD ANNALS: a continuous initiative for the improvement of type 2 diabetes care","volume":"199","author":"Russo","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2026012110525680800_CR25","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.2337\/dc08-0469","article-title":"Baseline quality-of-care data from a quality-improvement program implemented by a network of diabetes outpatient clinics","volume":"31","author":"Rossi","year":"2008","journal-title":"Diabetes Care"},{"key":"2026012110525680800_CR26","article-title":"The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes","volume":"31","author":"Ceriello","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026012110525680800_CR27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the Finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"2026012110525680800_CR28","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00592-023-02107-x","article-title":"2023 update on Italian guidelines for the treatment of type 2 diabetes","volume":"60","author":"Mannucci","year":"2023","journal-title":"Acta Diabetol"},{"key":"2026012110525680800_CR29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.025079","article-title":"Generalizability of FIGARO-DKD and FIDELIO-DKD trial criteria to the US population eligible for Finerenone","volume":"11","author":"Chiu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026012110525680800_CR30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12933-023-01840-5","article-title":"An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria","volume":"22","author":"Bramlage","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2026012110525680800_CR31","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/ndt\/gfac276","article-title":"Generalizability of DAPA-CKD trial to the real-world setting of outpatient CKD clinics in Italy","volume":"37","author":"Minutolo","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2026012110525680800_CR32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40620-019-00588-0","article-title":"Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics","volume":"32","author":"Minutolo","year":"2019","journal-title":"J Nephrol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02171-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02171-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/38\/2\/589\/66011044\/joneph_38_2_2171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02171-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/38\/2\/589\/66011044\/joneph_38_2_2171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:53:09Z","timestamp":1769010789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/2\/589\/8307215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,15]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,15]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02171-8","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3,1]]},"published":{"date-parts":[[2024,12,15]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Local ethics committees of each participating center approved the study protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All Authors declare: this research did not involve animals. The research was conducted on human subjects, following procedures in accordance with the ethical standards of the responsible Committees (this is a retrospective multicenter study) on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"Given the anonymous nature of the study, based on the Italian regulations, informed consent is not requested.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}